Information for healthcare professionals
Dr. Giuseppe Tarantini (Professor and Director of Interventional Cardiology, University of Padua, Italy) speaks on the importance of the early unloading concept in cardiogenic shock (CS), in bringing about improvements in systemic circulation ahead of coronary reperfusion, with the hope that this could improving mortality rates in such patients. The choice of left ventricular mechanical … Continue reading “Impella in Cardiogenic Shock: The Importance of Early Unloading”
Dr. Alex Truesdell of Virginia Heart discusses how a “team of teams” approach to treating cardiogenic shock can standardize care and improve outcomes. He also discusses the recent improvement in cardiogenic shock survival at Inova Heart and Vascular. After Inova Heart and Vascular Institute instituted a best practice protocol that includes early use of percutaneous … Continue reading “Dr. Alexander Truesdell: “Team of Teams” for Treating Cardiogenic Shock”
Dr. Alexander Truesdell, Interventional Cardiologist at Inova Heart and Vascular Institute discusses his editorial, the War on Shock, published in the Journal of Invasive Cardiology. The editorial compares his experience as a military physician with his experience as a cardiologist treating cardiogenic shock. Watch the video to learn which systems of care Dr. Truesdell suggests … Continue reading “Identifying Cardiogenic Shock Early with a Heart Team Approach”
A preponderance of evidence from the FDA cVAD Study, Impella Quality Assurance Database and physician-initiated National Cardiogenic Shock Initiative support the recommendation that placing Impella 2.5 or Impella CP pre-PCI improves outcomes.
Despite significant reduction in mortality in ST-segment elevation myocardial infarction (STEMI) following primary percutaneous coronary intervention (PCI), mortality rates in AMI complicated by cardiogenic shock (AMI-CGS) continues to be unacceptably high at about 50%.1 For Best Outcomes in AMI Cardiogenic Shock, Place Impella® or Impella CP® Pre-PCI Download this short bulletin that references scientific research … Continue reading “Early Initiation of Impella Support Pre-PCI: Key to Consistent and Reproducible Outcome of Improved Survival in AMICS”
Reference: J Am Coll Cardiol 2018; 72:1972-80 Cardiogenic shock continues to be the leading cause of death in patients with acute myocardial infarction (AMI).1 Despite implementation of guideline-recommended early revascularization, mortality rates in AMI complicated by cardiogenic shock (AMICS) remains constant at about 50%. Given that about 60,000 patients with AMI develop CS every year,2 … Continue reading “Improving Survival in Cardiogenic Shock by Adopting a Uniform Approach to Systems of Care”
Dr. Michael Amponsah of Central New York Cardiology/Mohawk Valley Health System shares a case of Impella CP for a non-ischemic cardiomyopathy patient who presented in cardiogenic shock. The patient, a 51 year old male was diagnosed with NYHA Class III non-ischemic systolic heart failure with an ejection fraction of 20% and an ICD. He presented … Continue reading “Dr. Michael Amponsah Cardiogenic Shock Case with Impella CP”
Navin Kapur, MD, executive director of the CardioVascular Center for Research and Innovation at Tufts Medical Center, discusses the results of the FDA STEMI Door-to-Unloading safety and feasibility randomized controlled trial. These results were presented at the American Heart Association Scientific Sessions 2018 in Chicago on Sunday, November 11. What did we learn from this pilot … Continue reading “The Door-to-Unloading (DTU) STEMI Safety & Feasibility Trial”
By completing this form, you are consenting to receiving emails regarding updates to the program, downloadable templates, case reviews, specialists opinions, and best practices.
Your personal information is important to us. Review our Privacy Policy and Terms of Use to learn how Abiomed protects your data.